WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock Ownership - Who owns Esperion Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Esperion Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Eric WarrenChief Commercial Officer2023-09-20742$1.25
$923.79Sell
Eric WarrenChief Commercial Officer2023-08-18243$1.41
$343.60Sell
Eric WarrenChief Commercial Officer2023-07-19106$1.59
$168.01Sell
Eric WarrenChief Commercial Officer2023-06-21603$1.48
$894.25Sell
Eric WarrenChief Commercial Officer2023-05-17219$1.62
$355.66Sell
J. Martin CarrollDirector2023-05-1123,091$1.57
$36.28kBuy
J. Martin CarrollDirector2023-05-108,409$1.49
$12.55kBuy
Stephen RocamboliDirector2023-05-108,111$1.50
$12.13kBuy
Sheldon L. KoenigPresident and CEO2023-05-0920,000$1.26
$25.20kBuy

1 of 1

ESPR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ESPR insiders and whales buy or sell their stock.

ESPR Shareholders

What type of owners hold Esperion Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Wasatch Advisors LP4.80%8,891,103$18.58MInstitution
Two Seas Capital LP4.15%7,686,120$16.06MInstitution
Vanguard Group Inc2.78%5,137,750$10.74MInstitution
Target N. V. Biotech2.42%4,477,964$9.36MInsider
Alta Partners Viii LP2.30%4,262,156$8.91MInsider
Bellevue Group Ag2.27%4,204,264$8.79MInstitution
Meditor Group Ltd2.05%3,791,300$7.92MInstitution
Aisling Capital Ii LP2.02%3,741,719$7.82MInsider
Millennium Management LLC1.86%3,449,451$7.21MInstitution
Longitude Capital Partners LLC1.82%3,368,792$7.04MInsider

1 of 3

ESPR vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ESPR38.79%21.23%Net Buying
ORGO6.24%93.76%Net SellingNet Selling
HROW30.73%69.27%Net SellingNet Buying
ACB54.59%0.00%
PROC0.22%76.27%
View Top Pharmaceutical Stocks

Esperion Therapeutics Stock Ownership FAQ

Who owns Esperion Therapeutics?

Esperion Therapeutics (NASDAQ: ESPR) is owned by 38.79% institutional shareholders, 21.23% Esperion Therapeutics insiders, and 39.98% retail investors. Target N. V. Biotech is the largest individual Esperion Therapeutics shareholder, owning 4.48M shares representing 2.42% of the company. Target N. V. Biotech's Esperion Therapeutics shares are currently valued at $9.54M.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.